As the Horizon acquisition reaps its benefits, Amgen is now turning eyes to its obesity and diabetes portfolio.

Discover why Amgen is a reliable wealth compounder with strong Q3 results, a promising pipeline, debt reduction, and ...

Wolfe Research analyst Alexandria Hammond initiated coverage of Amgen (AMGN) with a Peer Perform rating. With the antibody backbone, the firm ...

Nuevolution has been developing small molecule drugs since it was founded in 2001, focused on targets within inflammation, oncology ... produce marketable products. Amgen added that it does ...

Amgen ( AMGN 1.68%), a leader in biotechnology, released its third-quarter 2024 financial results on Oct. 30. The company ...

The company now counts on an extensive portfolio of blockbuster drugs across fields like oncology ... Beyond the products ...

further strengthening Amgen's position in the oncology market. Enbrel, one of Amgen's established products, faces challenges in the Medicare Part D negotiations, with a 67% discount to list price.

Amgen AMGN will report third ... However, lower revenues from oncology biosimilars (Kanjinti and Mvasi) and legacy established products are expected to hurt the top line. In the second half ...

Nuevolution has been developing small molecule drugs since it was founded in 2001, focused on targets within inflammation, oncology ... produce marketable products. Amgen added that it does ...